ArticleAntimicrobial agents and chemotherapy2020
Simultaneous Infection with
Open access · greenAbstract readCase Reports
In one paragraph
Article in Antimicrobial agents and chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 34 citations in OpenAlex.
- Clinical and genomic determinants associated with emergent ceftazidime-avibactam plus aztreonam non-susceptibility in ceftazidime-avibactam resistantAntimicrobial agents and chemotherapy · 2026Article
- Environmental redox conditions and strain variation define phenazine-mediated antagonism in co-infecting bacteria.PLoS biology · 2026Article
- Article
- Genomic diversity of clinically relevant bacterial pathogens from an acute care hospital in Suva, Fiji.JAC-antimicrobial resistance · 2025Article
- MvfR ShapesCells · 2025Article
- Analysis of intrahospital and global dissemination and resistome dynamics of NDM-1-producing ST773JAC-antimicrobial resistance · 2025Article
- Simultaneous clonal spread of NDM-1-producingIJID regions · 2024Article
- Emergence of NDM-1-ProducingMicroorganisms · 2024Article
- Tracing the origin of NDM-1-producing and extensively drug-resistant Pseudomonas aeruginosa ST357 in the Netherlands.BMC infectious diseases · 2024Article
- Molecular and clinical epidemiology of carbapenem resistantThe Lancet regional health. Western Pacific · 2024Article
- Genomic epidemiology and molecular characteristics of blaEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024Article
- Changing Genotypic Distribution, Antimicrobial Susceptibilities, and Risk Factors of Urinary Tract Infection Caused by Carbapenemase-ProducingAnnals of laboratory medicine · 2024Article
- Domestically Acquired NDM-1-Producing Pseudomonas aeruginosa, Southern California, USA, 2023.Emerging infectious diseases · 2023Article
- Three separate acquisitions of blaEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2023Article
- Article
- The Role of Colistin in the Era of New β-Lactam/β-Lactamase Inhibitor Combinations.Antibiotics (Basel, Switzerland) · 2022Review
- Epidemiology, Molecular Characteristics, and Virulence Factors of Carbapenem-ResistantInfection and drug resistance · 2022Article
- Evaluation of Susceptibility Testing Methods for Aztreonam and Ceftazidime-Avibactam Combination Therapy on Extensively Drug-Resistant Gram-Negative Organisms.Antimicrobial agents and chemotherapy · 2021Article
- Diversity and Distribution of Resistance Markers inMicroorganisms · 2021Review
- Comprehensive genome data analysis establishes a triple whammy of carbapenemases, ICEs and multiple clinically relevant bacteria.Microbial genomics · 2020Article
Corrections and comments
- Commented on by
Authors and funding
8 authors at 2 institutions in 2 countries.
Ayesha Khan *Center for Antimicrobial Resistance and Microbial Genomics, University of Texas Health Science Center, McGovern School of Medicine, Houston, Texas, USA.
William C Shropshire *Center for Antimicrobial Resistance and Microbial Genomics, University of Texas Health Science Center, McGovern School of Medicine, Houston, Texas, USA.
Blake HansonCenter for Antimicrobial Resistance and Microbial Genomics, University of Texas Health Science Center, McGovern School of Medicine, Houston, Texas, USA.
An Q DinhCenter for Antimicrobial Resistance and Microbial Genomics, University of Texas Health Science Center, McGovern School of Medicine, Houston, Texas, USA.
Audrey WangerCenter for Antimicrobial Resistance and Microbial Genomics, University of Texas Health Science Center, McGovern School of Medicine, Houston, Texas, USA.
Luis Ostrosky-ZeichnerCenter for Antimicrobial Resistance and Microbial Genomics, University of Texas Health Science Center, McGovern School of Medicine, Houston, Texas, USA.
Cesar A AriasCenter for Antimicrobial Resistance and Microbial Genomics, University of Texas Health Science Center, McGovern School of Medicine, Houston, Texas, USA Cesar.A.Arias@uth.tmc.edu William.R.Miller@uth.tmc.edu.
William R MillerCenter for Antimicrobial Resistance and Microbial Genomics, University of Texas Health Science Center, McGovern School of Medicine, Houston, Texas, USA Cesar.A.Arias@uth.tmc.edu William.R.Miller@uth.tmc.edu.ORCID 0000-0002-1518-2973
The University of Texas Health Science Center at Houston · USUniversidad El Bosque · CO
Funding
The LiaFSR system and antimicrobial peptide resistance in enterococciR01AI134637 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Cesar Augusto Arias · 2018 to 2026
$3.7MPOR Program on Genomic Prediction of Antimicrobial Resistance in VREK24AI121296 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2016 to 2025
$1.5MRole of YxdJK and DAK in the Enterococcal Envelope Stress ResponseK08AI135093 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MILLER, WILLIAM R · 2018 to 2022
$929kMolecular basis of the cefazolin inoculum effectR21AI143229 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2019 to 2020
$442kNIAID NIH HHS K08 AI135093NIAID NIH HHS K24 AI121296NIAID NIH HHS R01 AI134637NIAID NIH HHS R21 AI143229
Abstract
We report our clinical experience treating a critically ill patient with polymicrobial infections due to multidrug-resistant
Indexed as
Anti-Bacterial AgentsBacterial Proteinsbeta-LactamasesCandidaCandidiasisCritical IllnessEnterobacteriaceaeEnterobacteriaceae InfectionsEscherichia coliEscherichia coli ProteinsFemaleHumansIndiaKlebsiella pneumoniaeMiddle AgedPseudomonas aeruginosaAnti-Bacterial AgentsBacterial Proteinsbeta-lactamase NDM-1beta lactamase NDM-5, E colibeta-lactamase OXA-181, E colibeta-LactamasescarbapenemaseEscherichia coli ProteinsCandida auriscarbapenemaseEnterobacteriaceaeNDMpolymicrobial infectionPseudomonas aeruginosa
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.